Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
25.04
USD
+9.30%
-0.71%
-18.17%
This article is reserved for members
Not a member ?
Free registration
UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating
May. 10
MT
Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2
May. 09
MT
Transcript : Arrowhead Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 09, 2024
May. 09
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug
May. 03
MT
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Apr. 24
CI
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
Apr. 07
CI
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran
Mar. 25
CI
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise
Mar. 08
MT
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Mar. 08
CI
Certain Restricted Stock Units of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.
Mar. 02
CI
Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.
Mar. 02
CI
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024
Feb. 22
CI
B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating
Feb. 08
MT
Sector Update: Health Care Stocks Firmer Late Afternoon
Feb. 07
MT
Sector Update: Health Care Stocks Advance in Afternoon Trading
Feb. 07
MT
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating
Feb. 07
MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday
Feb. 07
MT
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines
Feb. 07
MT
Transcript : Arrowhead Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 06, 2024
Feb. 06
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Feb. 06
CI
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,860,019, According to a Recent SEC Filing
Feb. 02
MT
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024
Jan. 22
CI
Arrowhead Pharmaceuticals Insider Sold Shares Worth $292,804, According to a Recent SEC Filing
Jan. 08
MT
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,910, According to a Recent SEC Filing
Jan. 08
MT
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 08:15 AM
Jan. 08
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
More about the company
Last Close Price
25.04
USD
Average target price
53.77
USD
Spread / Average Target
+114.73%
Consensus
1st Jan change
Capi.
-18.17% 3.11B +7.52% 113B +11.38% 106B +0.58% 22.27B -12.64% 22.22B -3.90% 19.43B -37.85% 17.87B -8.58% 17.24B +7.77% 14.29B +37.41% 12.52B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**